Signs of T-cell Lymphoma

Dave Coulier Reveals 2nd Cancer Diagnosis in a Year

Dave Coulier Announces 2nd Cancer Diagnosis After Beating Non-Hodgkin Lymphoma

Dave Coulier announced he is undergoing treatment for tongue cancer nearly eight months after he beat his battle with non-Hodgkin lymphoma.

· 1d

Dave Coulier reveals new cancer diagnosis, 7 months after beating lymphoma

· 1d · on MSN

Dave Coulier says he is fighting another form of cancer, months after beating lymphoma

· 1d

Dave Coulier Says He’s Battling New Cancer After Beating Lymphoma

Dave Coulier, known for his role as Uncle Joey on “Full House,” announced on Tuesday that he is battling a new cancer, just seven months after sharing he had beaten non-Hodgkin lymphoma.

· 1d

What Type of Cancer Does Dave Coulier Have? Breaking Down the ‘Full House’ Alum’s New Diagnosis

IJR · 1d

‘Full House’ Star Reveals 2nd Cancer Diagnosis

· 1d

‘Full House’ star Dave Coulier reveals new cancer diagnosis months after beating lymphoma

“The silver lining here is that I had cancer, which helped me detect my other cancer.

AARP · 1d

‘Full House’ Star Dave Coulier Opens Up About Life After Two Cancer Diagnoses

· 1d

‘Full House’ star diagnosed with new cancer 7 months after beating Lymphoma

Health on MSN

We Asked a Doctor If Having Lymphoma Increases the Risk of Tongue Cancer

Dave Coulier’s new tongue cancer diagnosis raises questions about whether it’s linked to his prior lymphoma. Experts explain the risks, causes, and why second primary cancers can occur.

MedPage Today

'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9.6 months, with some responses lasting more than 2 years.

Pharmabiz

EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma

EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma: Lund, Sweden Tuesday, November 18, 2025, 11:00 Hrs [IST] BioInvent In

Medscape

NICE Approves CAR T-Cell Therapy for Patients With Lymphoma

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays disease progression and improves survival outcomes.